The DOI matches its Crossref record, with a small difference in title or year; 44 of the 44 references it cites were found in a registry or an index.
Esaxerenone (CS-3150) in Patients with Type 2 Diabetes and Microalbuminuria (ESAX-DN): Phase 3 Randomized Controlled Clinical Trial
Open accessAbstract
Background and objectives: Diabetic kidney disease is an important complication of type 2 diabetes. In a phase 2b study, adding esaxerenone to renin-angiotensin system inhibitors dose dependently reduced the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and microalbuminuria. This 52-week phase 3 study further investigated the effects of esaxerenone on the urinary albumin-to-creatinine ratio in this patient group. Design, setting, participants, & measurements: In this multicenter, randomized, double-blind study, patients with type 2 diabetes and a urinary albumin-to-creatinine ratio of 45 to <300 mg/g creatinine treated with renin-angiotensin system inhibitors were randomized to esaxerenone or placebo for 52 weeks ( n =455). Esaxerenone was initiated at 1.25 mg/d and titrated to 2.5 mg/d on the basis of serum potassium monitoring. The primary endpoint was the proportion of patients achieving urinary albumin-to-creatinine ratio remission (<30 mg/g creatinine and ≥30% reduction from baseline on two consecutive occasions). Results: Overall, 49 (22%) and nine (4%) patients in the esaxerenone and placebo groups, respectively, achieved urinary albumin-to-creatinine ratio remission (absolute difference 18%; 95% confidence interval, 12% to 25%; P< 0.001). The percent change in urinary albumin-to-creatinine ratio from baseline to end of treatment was significantly higher with esaxerenone versus placebo (−58% versus 8%; geometric least-squares mean ratio to placebo 0.38, 95% confidence interval, 0.33 to 0.44). There was a significant improvement with esaxerenone versus placebo in time to first remission (hazard ratio, 5.13; 95% confidence interval, 3.27 to 8.04) and time to first transition to urinary albumin-to-creatinine ratio ≥300 mg/g creatinine (hazard ratio, 0.23; 95% confidence interval, 0.11 to 0.48). More patients had a serum potassium level ≥6.0 or ≥5.5 mEq/L on two consecutive measurements in the esaxerenone group (20 [9%]) versus placebo (5 [2%]); these events were asymptomatic and resolved after dosage reduction or treatment discontinuation. Conclusions: Adding esaxerenone to existing renin-angiotensin system inhibitor therapy in patients with type 2 diabetes and microalbuminuria increased the likelihood of albuminuria returning to normal levels, and reduced progression of albuminuria to higher levels.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Novel nonsteroidal MRA, such as fi nerenone and esaxerenone, are more selective for mineralocorticoid receptors and have been noted to offer similar reductions in albuminuria but with a lower risk of hyperkalemia.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [161]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Esaxerenone lowered BP and albuminuria with limited changes in potassium, but long-term studies with clinical end points are lacking (85).”
From Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO) (2022) · cites this paper as [85]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Esaxerenone, another ns-MRA, has also been shown to lower urinary albumin excretion.”
The cited source says what the claim attributes to it.
In the citing paper
“However, the long-term kidney and cardiovascular bene fi ts of esaxerenone have not been established, and regulatory approval for esaxerenone is not widespread.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [161]
The cited source says what the claim attributes to it.
In the citing paper
“Similar to fi nerenone, another nonsteroidal MRA, esaxerenone, has also been shown to lower albumin excretion.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [161]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Revised Equations for Estimated GFR From Serum Creatinine in Japan
Matsuo, S., Imai, E., Horio, M., Yasuda, Y., Tomita, K., Nitta, K., Yamagata, K., Tomino, Y., Yokoyama, H., & Hishida, A. (2009) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2008.12.034 · Cited by 6,422
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Cosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz486 · Cited by 4,763
Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes
Bakris, G. L., Agarwal, R., Anker, S. D., Pitt, B., Ruilope, L. M., Rossing, P., Kolkhof, P., Nowack, C., Schloemer, P., Joseph, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2025845 · Cited by 2,935
Diabetic Kidney Disease: Challenges, Progress, and Possibilities
Alicic, R. Z., Rooney, M. T., & Tuttle, K. R. (2017) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.11491116 · Cited by 2,898
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes
Parving, H.-H., Lehnert, H., Bröchner-Mortensen, J., Gomis, R., Andersen, S., & Arner, P. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011489 · Cited by 2,873
[Effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes].
Parving, H., Lehnert, H., Brøchner‐Mortensen, J., Gomis, R., Andersen, S., & Arner, P. (2001) · PubMed · Cited by 2,535
The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019)
Umemura, S., Arima, H., Arima, S., Asayama, K., Dohi, Y., Hirooka, Y., Horio, T., Hoshide, S., Ikeda, S., Ishimitsu, T., et al. (2019) · Hypertension Research · doi:10.1038/s41440-019-0284-9 · Cited by 1,880
Self-citationViberti, G., & Wheeldon, N. M. (2002) · Circulation · doi:10.1161/01.cir.0000024416.33113.0a · Cited by 802
Bakris, G. L., Agarwal, R., Chan, J. C., Cooper, M. E., Gansevoort, R. T., Haller, H., Remuzzi, G., Rossing, P., Schmieder, R. E., Nowack, C., et al. (2015) · JAMA · doi:10.1001/jama.2015.10081 · Cited by 708
Dinneen, S. F. (1997) · Archives of Internal Medicine · doi:10.1001/archinte.1997.00440340025002 · Cited by 574 · cited 4×
“One of the typical signs of DKD is albuminuria, and the presence of albuminuria has been shown to be associated with higher cardiovascular risk (5).”
BackgroundInfluentialUpdate of pathophysiology and management of diabetic kidney disease
Lin, Y.-C., Chang, Y.-H., Yang, S.-Y., Wu, K.-D., & Chu, T.-S. (2018) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2018.02.007 · Cited by 562
Brenner, B. M., Cooper, M. E., & de Zeeuw, D. (2002) · ACC Current Journal Review · doi:10.1016/s1062-1458(01)00549-9 · Cited by 508
Heerspink, H. J. L., Greene, T., Tighiouart, H., Gansevoort, R. T., Coresh, J., Simon, A. L., Chan, T. M., Hou, F. F., Lewis, J. B., Locatelli, F., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30314-0 · Cited by 397
Self-citationCoresh, J., Heerspink, H. J. L., Sang, Y., Matsushita, K., Arnlov, J., Astor, B. C., Black, C., Brunskill, N. J., Carrero, J.-J., Feldman, H. I., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30313-9 · Cited by 338
Self-citationJapanese Clinical Practice Guideline for Diabetes 2016
Haneda, M., Noda, M., Origasa, H., Noto, H., Yabe, D., Fujita, Y., Goto, A., Kondo, T., & Araki, E. (2018) · Diabetology International · doi:10.1007/s13340-018-0345-3 · Cited by 319
Rossing, K., Schjoedt, K. J., Smidt, U. M., Boomsma, F., & Parving, H.-H. (2005) · Diabetes Care · doi:10.2337/diacare.28.9.2106 · Cited by 299
for the ORIENT study investigators, Imai, E., Chan, J. C. N., Ito, S., Yamasaki, T., Kobayashi, F., Haneda, M., & Makino, H. (2011) · Diabetologia · doi:10.1007/s00125-011-2325-z · Cited by 236
Self-citationMakino, H., Haneda, M., Babazono, T., Moriya, T., Ito, S., Iwamoto, Y., Kawamori, R., Takeuchi, M., Katayama, S., & for the INNOVATION Study Group (2007) · Diabetes Care · doi:10.2337/dc06-1998 · Cited by 230
Self-citationLacourcière, Y., Bélanger, A., Godin, C., Hallé, J.-P., Ross, S., Wright, N., & Marion, J. (2000) · Kidney International · doi:10.1046/j.1523-1755.2000.00224.x · Cited by 229 · cited 2×
“001 Patients with $30% reduction in UACR, n (%) 45 (20) 154 (69) 50 (41 to 57) ,0.”
Gaede, P. (2004) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfh470 · Cited by 223
Factors Associated With Frequent Remission of Microalbuminuria in Patients With Type 2 Diabetes
Araki, S.-I., Haneda, M., Sugimoto, T., Isono, M., Isshiki, K., Kashiwagi, A., & Koya, D. (2005) · Diabetes · doi:10.2337/diabetes.54.10.2983 · Cited by 216
Currie, G., Taylor, A. H. M., Fujita, T., Ohtsu, H., Lindhardt, M., Rossing, P., Boesby, L., Edwards, N. C., Ferro, C. J., Townend, J. N., et al. (2016) · BMC Nephrology · doi:10.1186/s12882-016-0337-0 · Cited by 214 · cited 3×
“7) Atrial fibrillation 6 (3) 6 (3) 12 (3) Antihypertensive agents ARB 214 (94) 209 (94) 423 (94) ACE inhibitor 13 (6) 13 (6) 26 (6) Other antihypertensive agents Calcium channel blocker 155 (68) 148 (67) 303 (67) Diuretics 26 (11) 16 (7) 42 (9) Alpha blocker 15 (7) 16 (7) 31 (7) Beta blockers 25 (11) 24 (11) 49 (11) N…”
BackgroundAgewall, S., Wikstrand, J., Ljungman, M., & Fagerberg, B. (1997) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)00312-3 · Cited by 184
Japanese Clinical Practice Guideline for Diabetes 2016
Haneda, M., Noda, M., Origasa, H., Noto, H., Yabe, D., Fujita, Y., Goto, A., Kondo, T., & Araki, E. (2018) · Journal of Diabetes Investigation · doi:10.1111/jdi.12810 · Cited by 181
Araki, S.-I., Haneda, M., Koya, D., Hidaka, H., Sugimoto, T., Isono, M., Isshiki, K., Chin-Kanasaki, M., Uzu, T., & Kashiwagi, A. (2007) · Diabetes · doi:10.2337/db06-1646 · Cited by 163
Lewis, E. J., Hunsicker, L. G., & al, W. R. C. (2002) · ACC Current Journal Review · doi:10.1016/s1062-1458(01)00550-5 · Cited by 151
Norris, K. C., Smoyer, K. E., Rolland, C., der Vaart, J. V., & Grubb, E. (2018) · BMC Nephrology · doi:10.1186/s12882-018-0821-9 · Cited by 126 · cited 4×
“7) Atrial fibrillation 6 (3) 6 (3) 12 (3) Antihypertensive agents ARB 214 (94) 209 (94) 423 (94) ACE inhibitor 13 (6) 13 (6) 26 (6) Other antihypertensive agents Calcium channel blocker 155 (68) 148 (67) 303 (67) Diuretics 26 (11) 16 (7) 42 (9) Alpha blocker 15 (7) 16 (7) 31 (7) Beta blockers 25 (11) 24 (11) 49 (11) N…”
BackgroundInfluentialEvidence-based Clinical Practice Guideline for CKD 2013
Japanese Society of Nephrology (2014) · Clinical and Experimental Nephrology · doi:10.1007/s10157-014-0949-2 · Cited by 125
Ito, S., Shikata, K., Nangaku, M., Okuda, Y., & Sawanobori, T. (2019) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.14751218 · Cited by 107
Self-citationPalmer, A. J., Annemans, L., Roze, S., Lamotte, M., Lapuerta, P., Chen, R. K., Gabriel, S., Carita, P., Rodby, R. A., de Zeeuw, D., et al. (2004) · Diabetes Care · doi:10.2337/diacare.27.8.1897 · Cited by 97
Microalbuminuria: target for renoprotective therapy PRO
Roscioni, S. S., Heerspink, H. J. L., & de Zeeuw, D. (2014) · Kidney International · doi:10.1038/ki.2013.490 · Cited by 93
Ruggenenti, P. L., Fassi, A., Parvanova, A. I., Iliev, I. P., Chiurchiu, C. R., Rubis, N., Gherardi, G., Ene‐Iordache, B., Gaspari, F., Perna, A., et al. (2010) · Journal of Hypertension · doi:10.1097/hjh.0b013e32834069bd · Cited by 85
The economic burden of progressive chronic kidney disease among patients with type 2 diabetes
Vupputuri, S. X., Kimes, T. M., Calloway, M. O., Christian, J. B., Bruhn, D. F., Martin, A. A., & Nichols, G. A. (2013) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2013.09.014 · Cited by 82 · cited 6×
“001 Patients with UACR ,30 mg/g creatinine, n (%) 9 (4) 49 (22) 18 (12 to 25) ,0.”
BackgroundInfluentialCollard, D., Brouwer, T. F., Engberink, R. O., Zwinderman, A. H., Vogt, L., & van den Born, B. H. (2020) · Hypertension · doi:10.1161/hypertensionaha.119.14659 · Cited by 65
Yang, C., Kor, C., & Hsieh, Y. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7110459 · Cited by 60 · cited 1×
“7) Atrial fibrillation 6 (3) 6 (3) 12 (3) Antihypertensive agents ARB 214 (94) 209 (94) 423 (94) ACE inhibitor 13 (6) 13 (6) 26 (6) Other antihypertensive agents Calcium channel blocker 155 (68) 148 (67) 303 (67) Diuretics 26 (11) 16 (7) 42 (9) Alpha blocker 15 (7) 16 (7) 31 (7) Beta blockers 25 (11) 24 (11) 49 (11) N…”
Glassock, R. J. (2010) · American Journal of Nephrology · doi:10.1159/000313553 · Cited by 54 · cited 2×
“Although controversy persists over whether therapies to decrease albuminuria can ultimately reduce rates of kidney failure in the clinical environment (11,12), data from a recent meta-analysis, using change in albuminuria as a surrogate endpoint over a median follow-up period of 3.”
Persson, F., Lindhardt, M., Rossing, P., & Parving, H.-H. (2016) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1177/1470320316652047 · Cited by 54 · cited 2×
“Early intervention strategies to delay the progression of albuminuria would be expected to have an important effect on life expectancy, quality of life, and health care expenditure in patients with diabetes (35).”
BackgroundPreventing and treating kidney disease in patients with type 2 diabetes
Delanaye, P., & Scheen, A. J. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1551362 · Cited by 47 · cited 2×
“5 mEq/L at baseline 4/87 (5) 13/94 (14) Population with serum potassium ,4.”
BackgroundClinical impact of reducing microalbuminuria in patients with type 2 diabetes mellitus
Araki, S., Haneda, M., Koya, D., Kashiwagi, A., Uzu, T., & Kikkawa, R. (2008) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2008.09.031 · Cited by 38 · cited 2×
“Improvement of albuminuria to normal levels has been reported to delay eGFR decline and kidney disease progression, and decrease cardiovascular event risk compared with type 2 diabetes patients with unchanged albuminuria (8,10,33,34).”
BackgroundBiomarkers and surrogate endpoints in kidney disease
Hartung, E. A. (2015) · Pediatric Nephrology · doi:10.1007/s00467-015-3104-8 · Cited by 36 · cited 2×
“Although controversy persists over whether therapies to decrease albuminuria can ultimately reduce rates of kidney failure in the clinical environment (11,12), data from a recent meta-analysis, using change in albuminuria as a surrogate endpoint over a median follow-up period of 3.”
BackgroundCurrie, G. E., Taylor, A. H., Jardine, A. G., et al. (2015) · Hypertension · doi:10.1161/hyp.66.suppl_1.p214
Cited by
KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
Rossing, P., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2022) · Kidney International · doi:10.1016/j.kint.2022.06.008 · Cited by 1,373
de Boer, I. H., Khunti, K., Sadusky, T., Tuttle, K. R., Neumiller, J. J., Rhee, C. M., Rosas, S. E., Rossing, P., & Bakris, G. (2022) · Diabetes Care · doi:10.2337/dci22-0027 · Cited by 919
“Esaxerenone lowered BP and albuminuria with limited changes in potassium, but long-term studies with clinical end points are lacking (85).”
BackgroundMolecular mechanisms and therapeutic targets for diabetic kidney disease
Tuttle, K. R., Agarwal, R., Alpers, C. E., Bakris, G. L., Brosius, F. C., Kolkhof, P., & Uribarri, J. (2022) · Kidney International · doi:10.1016/j.kint.2022.05.012 · Cited by 668
de Boer, I. H., Khunti, K., Sadusky, T., Tuttle, K. R., Neumiller, J. J., Rhee, C. M., Rosas, S. E., Rossing, P., & Bakris, G. (2022) · Kidney International · doi:10.1016/j.kint.2022.08.012 · Cited by 353
“Esaxerenone lowered BP and albuminuria with limited changes in potassium, but long-term studies with clinical end points are lacking (85).”
BackgroundRossing, P., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2022) · Kidney International · doi:10.1016/j.kint.2022.06.013 · Cited by 274
“However, the long-term 994 kidney and cardiovascular benefits of esaxerenone have not been established, and regulatory approval for esaxerenone is, so far, limited to treatment of hypertension in Japan.28,29 The Work Group judged that the majority of wellinformed patients with T2D who had persistent albuminuria (ACR >…”
Background
Metadata
- Authors
- Ito, S., Kashihara, N., Shikata, K., Nangaku, M., Wada, T., Okuda, Y., & Sawanobori, T.
- Affiliations
- Tohoku University (JP)
- Kawasaki Medical School (JP)
- Okayama University Hospital (JP)
- The University of Tokyo (JP)
- Kanazawa University (JP)
- Daiichi-Sankyo (Japan) (JP)
- Corresponding author
- Ito, Sadayoshi
- Venue
- Clinical Journal of the American Society of Nephrology
- Published
- 2020-11-25
- Volume
- 15
- Issue
- 12
- Pages
- 1715-1727
- ISSN
- 1555-9041 (ISSN-L)
- 1555-905X
- PMC
- PMC7769030
- OpenAlex
- W3107151441
- Cited by
- 234
- References
- 42
- Citations by year
- 2026: 30 · 2025: 40 · 2024: 46 · 2023: 46 · 2022: 46 · 2021: 25 · 2020: 1
- FWCI
- 18.51
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Clinical Journal of the American Society of Nephrology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Daiichi Sankyo Co., Ltd
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- One, type 2 diabetes, microalbuminuria, diabetic nephropathy, albumin-creatinine ratio, renin-angiotensin system inhibitors, mineralocorticoid receptor antagonists, serum potassium, renal protection, hospitalization
- MeSH terms
- Aged, Albuminuria, Mineralocorticoid Receptor Antagonists, Creatinine, Diabetes Mellitus, Type 2, Female, Humans, Japan, Kidney, Male, Middle Aged, Pyrroles, Remission Induction, Risk Factors, Sulfones, Time Factors, Biomarkers, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.